Association of American Physicians

Syncromune® Inc. Expands Scientific Advisory Board with Addition of Prominent Oncology Trailblazer James Armitage, M.D.

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, Association of American Physicians, Faculty, American College, ASCO, Dean, MD Anderson Cancer Center, Vice, Clinical professor, Hematology, American Society of Clinical Oncology, Advisory board, University of Nebraska Medical Center, Department of Medicine – University of Pamplona, Clinical Oncology, Society, Internal medicine, UNMC, College, Membership of the Royal College of Physicians of Ireland, Royal college, Nebraska Medicine, Division, Richard, University, American College of Physicians, Mayo Clinic, Cancer, Patient, American Association for Cancer Research, Transplant, Book, Coronavirus Scientific Advisory Board, Pharmaceutical industry, Nursing, Medical device, Physician

Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.

Key Points: 
  • Syncromune®, Inc., a clinical-stage biopharmaceutical company focused on the development of SYNC-T™, a disruptive platform technology designed to synchronize in situ neoantigen T cell education and immunostimulation via a drug/device combination therapy, proudly announces the addition of James Armitage, M.D., to its Scientific Advisory Board as the Advisory Board Chair.
  • Dr. Armitage has served as President of both the American Society for Transplantation and Cellular Therapy (ASTCT) and the American Society of Clinical Oncology (ASCO).
  • “We are deeply honored to have Dr. Armitage join Syncromune’s Scientific Advisory Board as chair,” stated Eamonn Hobbs, President and CEO of Syncromune.
  • He has authored or co-authored more than 600 articles and 100 book chapters and is the editor/co-editor of 27 books.

The FNIH Awards 2023 Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D., from Memorial Sloan Kettering Cancer Center for Pancreatic Cancer Research

Retrieved on: 
Thursday, August 24, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Memorial Sloan Kettering Cancer Center, Pancreatic cancer, American Society for Clinical Investigation, GSK, Survivor, Trailblazer, FNIH, University, Awards ceremony, Disability, Neoplasm, Physician, Cancer, University of Iowa, American Physician Scientists Association, Biomedical sciences, AAP, Research, Bangladesh Technical Education Board, Messenger, Association of American Physicians, Charles, Global Smoke-Free Partnership Award, Patient, World Cultural Council 31st Award Ceremony, MSK, Edmond, Society, Pharmaceutical industry, Vaccine

The Foundation for the National Institutes of Health (FNIH) has awarded its sixth annual Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D.

Key Points: 
  • The Foundation for the National Institutes of Health (FNIH) has awarded its sixth annual Trailblazer Prize for Clinician-Scientists to Vinod Balachandran, M.D.
  • , at Memorial Sloan Kettering Cancer Center (MSK), for his groundbreaking research on immunotherapies for pancreatic cancer.
  • This pioneering work has the potential to transform the treatment of pancreatic cancer, one of the deadliest malignancies, and provide proof of concept for future cancer vaccines.
  • He is also immunology group leader in the David M. Rubenstein Center for Pancreatic Cancer Research at MSK.

Appia Bio Announces Appointment of Robert S. Negrin, M.D., to Scientific Advisory Board

Retrieved on: 
Thursday, December 15, 2022
Faculty, University of Southern California, NKT, International Society, Association of American Physicians, Harvard University, Society, Hematology, Patient, Science, TCR, Cancer, Allotransplantation, California Institute of Technology, Doris Duke, Research, Biomedical engineering, Biology, Knowledge, Stanford University, Division, Stem cell, Medicine, Chemical engineering, Health, Haematopoietic system, Developmental Biology (journal), Multimedia, Coronavirus Scientific Advisory Board (Turkey), CAR, USC, University, Physician, Engineering, Regenerative medicine, ACUA, Berkeley, Vaccine, Dentistry, Pharmaceutical industry, Blood

LOS ANGELES, Dec. 15, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor natural killer T (CAR-NKT) cell therapies for cancer patients, today announced the appointment of Robert S. Negrin, M.D., to its Scientific Advisory Board.

Key Points: 
  • LOS ANGELES, Dec. 15, 2022 /PRNewswire/ -- Appia Bio, Inc., a preclinical-stage biotechnology company developing allogeneic chimeric antigen receptor natural killer T (CAR-NKT) cell therapies for cancer patients, today announced the appointment of Robert S. Negrin, M.D., to its Scientific Advisory Board.
  • Dr. Negrin is one of the world's leading experts in hematology and cellular immunology and joins Appia Bio's scientific founders in advising the Company's research and development.
  • "We are thrilled to have Dr. Negrin join our world-class Appia Bio Scientific Advisory Board.
  • Dr. Negrin joins Appia Bio's Scientific Advisory Board and Scientific Founders in advising the company, comprised of the following leaders in immunology, immuno-oncology, and cell therapy engineering:
    Irving Weissman, M.D., director, Stanford Institute for Stem Cell Biology and Regenerative Medicine, Virginia & D.K.

InvisiShield Technologies Announces the Appointment of Warner C. Greene, M.D., Ph.D. as President and Chief Scientific Officer

Retrieved on: 
Wednesday, November 16, 2022
Health, Infectious Diseases, Health Technology, COVID-19, Pharmaceutical, Biotechnology, University of California, San Francisco, Gladstone Institutes, American Academy, Warner, Mouse, Nasal cavity, Association of American Physicians, Physician, Washington University School of Medicine, RSV, AIDS, Howard Hughes Medical Institute, Internal medicine, Stanford University, Duke University Hospital, Nick, National academy, Long COVID, Severe acute respiratory syndrome coronavirus 2, Doctor of Philosophy, Vaccination, National Cancer Institute, COVID, National Academy of Medicine, Immunology, Hospital, Research, Science, Senior advisor, Pharynx, Urinary tract infection, Person, Microbiology, UCSF, Massachusetts General Hospital, Viral load, Immunodeficiency, COVID-19, University, Infection, Harvard University, Risk, MD, Vaccine, Pharmaceutical industry, Virology, William Ewart Gladstone, Medicine, San Francisco Bay Area

InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses today announced the appointment of Warner C. Greene, M.D., Ph.D., as President and Chief Scientific Officer.

Key Points: 
  • InvisiShield Technologies Ltd., a pre-clinical-stage biotechnology company focused on developing intranasal preventives for major disease-causing respiratory viruses today announced the appointment of Warner C. Greene, M.D., Ph.D., as President and Chief Scientific Officer.
  • Like many of us at Gladstone, Warners lab rapidly pivoted to work on SARS-CoV-2 in 2020.
  • We are thrilled for Warner that he is now joining InvisiShield to lead an innovative approach to preventing the spread of COVID-19 and reducing the risk of long COVID.
  • My goal is to bring our intranasal preventive spray for SARS-CoV-2 to people faster, said Dr. Greene.

Feinstein Institute researcher nominated to Association of American Physicians

Retrieved on: 
Tuesday, April 24, 2018
Northwell Health, Healthcare in New York, Town of North Hempstead, New York, Feinstein Institute for Medical Research, Association of American Physicians, Health, Yousef Al-Abed, Peter K. Gregersen

MANHASSET, N.Y., April 24, 2018 /PRNewswire-USNewswire/ --Northwell Health's Feinstein Institute for Medical Research Professor John, M Kane, MD , has been inducted into the prestigious Association of American Physicians (AAP).

Key Points: 
  • MANHASSET, N.Y., April 24, 2018 /PRNewswire-USNewswire/ --Northwell Health's Feinstein Institute for Medical Research Professor John, M Kane, MD , has been inducted into the prestigious Association of American Physicians (AAP).
  • AAP's members are competitively selected and are among the leading senior physician scientists from the United States, Canada and other countries.
  • His current work focuses on early intervention programs for patients with mental illness to help improve their outcomes and the severity of their condition.
  • The Feinstein Institute for Medical Research is the research arm of Northwell Health, the largest healthcare provider in New York.